Author | Ghanshyam Yadav, MD | OncLive

Author | Ghanshyam Yadav, MD

Articles

Dr. Yadav on Differences in Type 1 and Type 2 Uterine Cancer

November 12, 2019

Video

Ghanshyam Yadav, MD, discusses the differences between type 1 and type 2 uterine cancer.

Dr. Yadav on the Olaparib/Neratinib Combo in HER2+ Uterine Serous Carcinoma

September 10, 2019

Video

Ghanshyam Yadav, MD, discusses research surrounding the combination of the PARP inhibitor olaparib and the pan-HER TKI neratinib, which proved to be highly synergistic and had significant activity in preclinical models of HER2-positive uterine serous carcinoma.

Dr. Yadav on the Synergy of a Novel Combination in Uterine Serous Carcinoma

April 12, 2019

Video

Ghanshyam Yadav, MD, first-year resident, Baylor College of Medicine, discusses the synergy of a novel combination in the treatment of patients with HER2-overexpressing uterine serous carcinoma.

Dr. Yadav on Olaparib/Neratinib in HER2-Overexpressing Uterine Serous Carcinoma

March 29, 2019

Video

Ghanshyam Yadav, MD, first-year resident, Baylor College of Medicine, discusses the combination of olaparib (Lynparza) and neratinib (Nerlyx) in patients with HER2-overexpressing uterine serous carcinoma.

x